Patent details

Basic Information

Publication number:

EP2521543

PCT Application Number:

PCT/US/2011/020160

Type:

European Patent Granted for LU

Legal Status:

Lapsed

Application number:

EP117002881

PCT Publication Number:

WO/2011/084968

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

A COMBINATION OF AN IMMUNOMODULATORY COMPOUND AND AN ARTEMISININ DERIVATIVE FOR TREATING CANCER

French Title of Invention:

ASSOCIATION D'UN COMPOSÉ IMMUNOMODULATEUR ET D'UNE DÉRIVÉ D'ARTÉMISININE POUR LE TRAITEMENT DU CANCER

German Title of Invention:

KOMBINATION AUS EINER IMMUNMODULATORISCHEN VERBINDUNG UND EINEM ARTEMISININ DERIVAT ZUR BEHANDLUNG VON KREBS

SPC Number:

Dates

Filing date:

05/01/2011

Grant date:

13/04/2016

EP Publication Date:

13/04/2016

PCT Publication Date:

14/07/2011

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

14/11/2012

EP B1 Publication Date:

13/04/2016

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

05/01/2017

Expiration date:

05/01/2031

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

05/01/2011

 

 

Name:

Celgene Corporation

Address:

86 Morris Avenue, Summit, NJ 07901, United States (US)

Inventor

1

Name:

GRAVETT Andrew

Address:

United Kingdom (GB)

2

Name:

DALGLEISH Angus

Address:

United Kingdom (GB)

3

Name:

LIU Wai

Address:

United Kingdom (GB)

Priority

1

Priority Number:

292307 P

Priority Date:

05/01/2010

Priority Country:

United States (US)

2

Priority Number:

371347 P

Priority Date:

06/08/2010

Priority Country:

United States (US)

Classification

Main IPC Class:

A61K 31/454;

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages